Jun 3, 2020 Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering Learn More
May 26, 2020 Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia Learn More